|
Imaging Biometrics Ltd on Monday said it has successfully completed the phase one trial evaluating oral gallium maltolate for the treatment of recurrent or relapsed glioblastoma. The London-based healthcare imaging software firm said the trial met all predefined phase one objectives, including safety, tolerability, and pharmacokinetic benchmarks. In response, shares in Imaging Biometrics closed up 57% at 1.18 pence on Monday in London. The firm said significant adverse events were not observed, which underscores gallium maltolate’s safety profile. Oral GaM is a novel therapeutic candidate that targets tumour metabolism and iron-dependent cancer growth. ‘This achievement marks a pivotal step forward in our mission to bring novel, mechanism-driven therapies to patients with GBM,’ said Imaging Biometrics Chief Executive Officer Trevor Brown. ‘We are encouraged by the data and the continued treatment of one long-standing patient, which speaks to GaM’s potential clinical benefit. We look forward to sharing the full summary analysis soon.’ With phase one complete, Imaging Biometrics said it is ‘actively engaging’ with cancer centres to start a phase two trial aimed at further evaluating GaM’s efficacy and expanding its clinical footprint. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
